Roivant Sciences Ltd. (ROIV)

NASDAQ · Healthcare · analysed November 9, 2026

Founded in 2014, Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company that develops and commercializes innovative therapeutics through a decentralized model of nimble, focused subsidiary companies known as "Vants". The company primarily targets indications with high unmet medical needs, with a core concentration in immunology, inflammation, and rare diseases. Roivant's current strategic priorities focus on advancing late-stage clinical programs, including its anti-FcRn antibody pipeline led by IMVT-1402 via Immunovant, progressing and commercializing the TYK2/JAK1 inhibitor brepocitinib across severe autoimmune conditions via Priovant, and evaluating mosliciguat for pulmonary hypertension.

Roivant Sciences Ltd.ROIV / NASDAQ / analysed November 9, 2026

BullishnessHow the evidence compares with what the market already expects, from 1 to 10. It is about the stock at its current price, not the business alone. Not a price target or a forecast.6.2

CertaintyHow complete and consistent the evidence is, from 1 to 10. It says nothing about which way the evidence points, and it is not the probability that the analysis is right.6.4

MoatWeak

Executive summary

Roivant Sciences is transitioning from a clinical-stage development model into a commercial biopharmaceutical company following the August 2026 FDA accelerated approval of LISRAYA in adult dermatomyositis^12,14. Recent Phase 3 clinical success for brepocitinib in non-infectious uveitis and an oral argument at the Federal Circuit regarding a 1.3 billion dollar contingent patent settlement provide significant near-term pipeline and liquidity momentum^4,5,8. However, trailing revenue remains negligible at 8.26 million dollars against an annual cash burn of 758.6 million dollars, meaning future returns depend heavily on commercial execution and clinical de-risking against entrenched category leaders^1,2.

Sources cited here, 7 of 30

Key figures

Market cap: $25.9B
Revenue growth, fiscal year to Mar 2026: -71.6%
Net margin, fiscal year to Mar 2026: -3611.7%

Market cap and P/E as found on November 9, 2026.

About this analysis

Produced by qualiscore.ai on November 9, 2026. It is generated automatically by a language model from public sources found by live web search, and is published automatically. Many analyses are reviewed by a person afterwards, but not all of them.

Bullishness rates how the evidence compares with what the market already expects, on a scale from 1 to 10. Certainty rates how complete and consistent that evidence is. Neither is a price target or a forecast, and both can change with the next analysis. How the scores are produced · How to check an AI stock analysis.

This is not investment advice and not a recommendation to buy, sell or hold any security. It does not consider your circumstances. The operator of qualiscore.ai may hold positions in securities discussed on this site. Liability is excluded.

Found a factual error in this analysis? Report an error, ideally with where the correct information can be found.

Roivant Sciences Ltd. (ROIV)

Executive summary

Sources cited here, 7 of 30

Key figures

Related analyses